الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 123 |  |  |
| | | from | 123 | | |
Abstract
There is an increasing interest in the use of PT/Cy as GVHD prophylaxis, both in the haploidentical and in the HLA-identical setting. The main advantages of this technique are an improved effect on GVHD control without any complex procedure such as graft manipulation. Moreover, its safety profile is good when compared to previous strategies. This can be seen not just from a very low rate of graft failure but also in an acceptable incidence of infective complications (especially viral complications).
Cyclophosphamide has a unique mechanism of action. It selectively destroys rapidly proliferating donor- and host-alloreactive CD4 cells while sparing slowly proliferating cells. The selective nature of cyclophosphamide activity permits rapid immune reconstitution and conceivably preserves the GVL effect. In matched related and unrelated donor transplants, cyclophosphamide alone is active, with a notably low incidence of chronic GVHD.
Several important benefits of single-agent GVHD prophylaxis with post-transplantation cyclophosphamide are noteworthy. First, PTCy is inexpensive, easy to administer, and readily available, making this regimen feasible in less developed countries. Second, limiting post-transplantation immunosuppression, specifically by eliminating prolonged calcineurin inhibition, permits reconstitution of the immune system in an environment free of ongoing pharmacologic regulation.
In our study we tried to assess safety and efficacy of using cyclophosphamide as GVHD prophylaxis in allogeneic stem cell transplant and its effect on acute GVHD, chronic GVHD, infections and drug toxicities in comparison with conventional GVHD prophylaxis.